Citi raised the firm’s price target on Rigel Pharmaceuticals to $4 from $3 and keeps a Buy rating on the shares. The analyst says the company’s Q4 revenue were as expected given the pre-announcement in January.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RIGL:
- New Corporate Activity and Growth Risk for Rigel Pharmaceuticals – What’s the Latest?
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Rigel Pharmaceuticals reports Q4 EPS 0c, consensus (3c)
- Options Volatility and Implied Earnings Moves Today, March 05, 2024
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
